Real-world study of chemotherapy plus immunotherapy for advanced endometrial cancer

This is a real-world study that follows patients with advanced or recurrent endometrial cancer who are already receiving standard treatment (chemotherapy followed by durvalumab, an immunotherapy medication). Researchers want to understand how well durvalumab works—both on its own and when combined with another medication called olaparib—and how these treatments affect patients' daily lives and well-being. The study will collect information from medical records and ask patients to fill out questionnaires about their experience.

Endometrial cancer is a serious disease, and while new immunotherapy treatments have shown promise, doctors need real-world information about how these medications perform in everyday practice and which patients benefit most from them.